Saturday 17 October 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024. In the quarter to June 2026, revenue fell 1.92%, EPS grew 14.0% and free cash flow grew 58.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

533.12 8.39 −1.55%

Follow UTHR

Alert me

Market cap: $23.2B
P/E: 17.6×
Fwd P/E: 20.1×
Dividend yield: —
F-score: 8/9
Altman Z: 19.55
Beneish M: −2.26
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.86

Total sells 1,379.26

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	—	—	—
Sell	19	23	11	10	37	32	32	30	25	23	25	11

Insider Ownership 2.70%

Capital & Financial Ratios $m

Market Cap 23,230.00

Revenue 3,154.50

Net Income 1,310.90

Free Cash Flow 1,093.00

Net Debt (2,662.30)

Current Ratio 5.73

Debt/Equity 0.00

P/E ratio 17.61

Fwd P/E 20.10

P/S ratio 7.20

P/B ratio 3.55

Past 5Y EPS Growth 19.28%

This Y EPS Growth (5.06%)

Next Y EPS Growth 17.62%

Next Y revenue growth (0.74%)

Next 5Y EPS Growth 8.39%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 86.75%

10-year low 10-year high

P/S against its own 10 years 96.17%

10-year low 10-year high

P/B against its own 10 years 94.10%

10-year low 10-year high

EV/Sales against its own 10 years 96.24%

10-year low 10-year high

EV/FCF against its own 10 years 95.57%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2,994	3,267	2,920	2,662
Receivables	279	279	350	310
Inventory	112	158	183	194
Other	166	170	249	317
	3,551	3,874	3,703	3,484

	2023	2024	2025	Q'26
Payables	298	345	488	498
ST’ Debt	400	300	—	—
Other	106	94	73	110
	804	738	561	608

Compound Annual Growth %

	10y	5y	3y
Sales	8.06%	16.50%	18.02%
Cash Flow	15.09%	15.62%	24.84%
Earnings	7.43%	20.99%	22.43%
Book Value	16.15%	15.89%	13.94%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	782	783	—	—	—
’25	794	799	800	790	3,183
’24	678	715	749	736	2,877
’23	507	597	609	615	2,328
’22	462	467	516	492	1,936
’21	379	447	445	415	1,686
’20	356	362	380	385	1,483

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	463	314	—	—	—
’25	461	192	562	346	1,561
’24	377	232	377	341	1,327
’23	375	106	346	151	978
’22	289	127	259	128	803
’21	90	148	186	175	598
’20	215	164	251	126	756

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	363	206	—	—	—
’25	386	130	346	173	1,035
’24	338	187	301	255	1,081
’23	334	62	281	72	748
’22	275	110	190	89	664
’21	79	132	162	104	477
’20	202	146	238	114	699

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	5.82	7.27	—	—	—
’25	6.63	6.41	7.16	7.70	27.86
’24	6.17	5.85	6.39	6.19	24.64
’23	4.86	5.24	5.38	4.36	19.81
’22	5.03	2.41	4.91	2.67	15.00
’21	0.61	3.65	3.42	2.35	10.06
’20	3.12	2.41	3.84	2.19	11.54

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	97.52	112.01	100.06	74.31	75.58	150.73	158.38	204.44	208.62	266.98	Analyst estimates 2026–2028 Powerpack
	High	159.96	169.89	152.55	128.94	152.82	218.38	283.09	279.14	417.82	519.99
People
People	Employees	750	800	860	920	950	965	985	1,168	1,305	1,400
	Revenue/emp, $m	2.13	2.16	1.89	1.57	1.56	1.75	1.97	1.99	2.20	2.27
Income, $m
Income, $m	Revenue	1,599	1,725	1,628	1,449	1,483	1,686	1,936	2,328	2,877	3,183
	Gross margin, %	95.45	93.87	87.79	91.88	92.71	92.73	92.17	88.94	89.24	87.92
	EBT	1,060	770	759	(165)	639	594	951	1,274	1,539	1,714
	EBT margin, %	66.31	44.60	46.62	(11.39)	43.07	35.24	49.09	54.75	53.49	53.85
	Net income	714	418	589	(104)	515	476	727	985	1,195	1,335
	Depreciation	32	31	36	46	50	50	51	53	73	86
Per share, $
Per share, $	Revenue	36.50	39.21	37.42	33.08	33.56	37.54	42.56	49.73	63.66	71.84
	Earnings	16.29	9.50	13.54	(2.39)	11.65	10.60	15.98	21.04	26.44	30.13
	Cash flow	14.69	10.78	17.89	(4.72)	17.10	13.32	17.64	20.90	29.36	35.24
	Capex	(0.87)	(1.77)	(4.24)	(1.91)	(1.29)	(2.69)	(3.05)	(4.92)	(5.45)	(11.87)
	Free cash flow	13.83	9.00	13.66	(6.63)	15.81	10.63	14.59	15.97	23.91	23.37
	Book value	42.27	47.77	64.11	63.48	76.81	88.17	105.42	127.88	142.57	160.19
	Shares, m	44	44	44	44	44	45	46	47	45	44
Valuation, ×
Valuation, ×	P/E	8.89	15.88	8.01	0.00	13.03	20.40	17.07	10.80	13.34	16.14
	P/S	3.94	3.87	2.91	2.66	4.52	5.76	6.42	4.57	5.54	6.78
	P/B	3.41	3.18	1.70	1.39	1.98	2.45	2.59	1.78	2.47	3.04
	EV/Sales	3.29	3.63	2.35	2.22	3.99	5.23	5.50	3.59	4.55	5.96
	EV/FCF	8.76	16.01	6.49	(10.90)	8.54	18.68	16.17	11.24	12.16	18.32
Cash, $m
Cash, $m	Operating cash flow	644	474	778	(207)	756	598	803	978	1,327	1,561
	Capex	(38)	(78)	(184)	(84)	(57)	(121)	(139)	(230)	(246)	(526)
	Free cash flow	606	396	594	(290)	699	477	664	748	1,081	1,035
Balance, $m
Balance, $m	Working capital	1,092	1,003	1,491	1,402	1,844	2,018	3,037	2,747	3,136	3,142
	Total debt	—	250	250	850	800	800	800	700	300	—
	Net debt	(1,051)	(677)	(1,166)	(636)	(1,035)	(1,131)	(2,039)	(2,294)	(2,967)	(2,920)
	Shareholders’ equity	1,851	2,102	2,789	2,780	3,395	3,959	4,797	5,985	6,444	7,096
Returns, %
Returns, %	ROA	31.65	16.06	18.76	(2.86)	12.07	9.73	12.97	14.91	16.45	17.51
	ROIC	82.89	35.76	31.02	(5.47)	15.72	12.28	22.20	20.07	24.75	22.34
	ROE	41.50	21.14	24.10	(3.75)	16.67	12.94	16.61	18.27	19.23	19.71

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TAK Takeda Pharmaceutical Co.	$61.9B	29.6×	—	+1.71% (above 0%: growing)	−4.35% (below 0%: shrinking)	−95.56% (below 0%: shrinking)	66.66%	16.51%	Compare
TEVA Teva Pharmaceutical Industries Ltd.	$47.9B	65.9×	30.7×	−0.81% (below 0%: shrinking)	n/m	+121.43% (above 0%: growing)	51.98%	(2.03%)	Compare
HLN Haleon PLC Sponsored ADR	$43.7B	22.6×	17.6×	−0.32% (below 0%: shrinking)	+40.00% (above 0%: growing)	−42.94% (below 0%: shrinking)	62.88%	25.36%	Compare
ZTS Zoetis Inc.	$32.4B	13.0×	12.3×	−0.24% (below 0%: shrinking)	+2.48% (above 0%: growing)	+17.43% (above 0%: growing)	72.73%	37.56%	Compare
UTHR United Therapeutics Corporation	$23.2B	17.6×	20.1×	−1.92% (below 0%: shrinking)	+13.99% (above 0%: growing)	+58.76% (above 0%: growing)	87.30%	42.23%
VTRS Viatris Inc.	$20.9B	— (loss-making)	61.1×	+4.88% (above 0%: growing)	n/m	+101.08% (above 0%: growing)	38.77%	0.17%	Compare
NBIX Neurocrine Biosciences, Inc.	$13.9B	19.2×	30.5×	+39.49% (above 0%: growing)	+31.19% (above 0%: growing)	+43.69% (above 0%: growing)	97.58%	15.80%	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
Median of peers	$26.7B	26.1×	30.5×	+0.74%	+16.84%	+26.50%	60.61%	11.89%

All 86 Drug Manufacturers Specialty & Generic stocks →

United Therapeutics Corporation (UTHR) key facts

Strength: United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
Strength: Net income was $1.3 billion, or $30.13 per share (basic), a net margin of 41.9%.
United Therapeutics Corporation (UTHR) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, UTHR traded at $533.12, a market capitalization of $23.2 billion.
At that price the stock trades at 17.6× trailing-twelve-month earnings and 7.2× sales; its P/E is higher than 87% of its own readings over the past ten years.
Return on equity was 19.7% and debt-to-equity 0.00.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 19.55 (safe zone) for fiscal 2025.